Celltrion’s RemdantryTM, previously known as Inflectra®, will be available in Canada as of April 1, 2025

TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced that RemdantryTM will be available in Canada as of April 1, 2025. RemdantryTM, previously known as Inflectra®, is the new brand name for its first monoclonal antibody biosimilar to Remicade (infliximab) in Canada. Celltrion received Health Canada Notice of Compliance (NOC) for Remdantry on March 7, 2025. RemdantryTM will use the same Drug Identification Number (DIN) as Inflectra®, and the formulation,